Richard A. Fair

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Houston, TX
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Ben Hohl, by power of attorney
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Richard A. Fair

Form 4 holding PRESIDENT AND CEO, Director

Enliven Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
875,000
Estimated value
Report date
11 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director

BELLICUM PHARMACEUTICALS, INC

Security class
Stock Option (right to buy)
Shares / value
400,000
Estimated value
Report date
15 Aug 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Clovis Oncology, Inc.

Security class
Stock Option (right to buy)
Shares / value
42,223
Estimated value
Report date
10 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Richard A. Fair

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .